IRADIMED insider trust reports Rule 10b5-1 sales

IRADIMED CORP insider activity centers on trust-managed share sales linked to CEO Roger E. Susi.

Rhea-AI Filing Summary

IRADIMED CORP insider activity centers on trust-managed share sales linked to CEO Roger E. Susi. On January 26, 2026, the Phillip Susi 2008 Dynasty Trust sold 4,339 common shares at a weighted average price of $100.54 and 661 shares at $101.38, both under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025.

After these sales, that trust held 2,262,500 shares. The filing also lists 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with Susi expressly disclaiming beneficial ownership of the latter beyond his pecuniary interest.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 4 txns

Insider Susi Roger E.

Role CEO, PRESIDENT, CHAIRMAN

Sold 5,000 shs ($503K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,339	$100.54	$436K
Sale	Common Stock	661	$101.38	$67K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,262,500 shares (Indirect, By Phillip Susi 2008 Dynasty Trust); Common Stock — 162,950 shares (Indirect, By Roger E. Susi Revocable Trust); Common Stock — 2,062,500 shares (Indirect, By Matthew Susi 2008 Dynasty Trust)

Footnotes (4)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $100.05 to $100.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. F3. This transaction was executed in multiple trades at prices ranging from $101.14 to $101.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. F4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IRADIMED (IRMD) report in this Form 4?

The Form 4 reports common stock sales by the Phillip Susi 2008 Dynasty Trust associated with IRADIMED CEO Roger E. Susi. It discloses two planned sales, remaining indirect holdings across multiple trusts, and clarifies Susi’s beneficial ownership through an explicit disclaimer for one of the trusts.

How many IRADIMED shares were sold and at what prices on January 26, 2026?

The trust sold 4,339 IRADIMED common shares at a weighted average price of $100.54 and 661 shares at $101.38. Both transactions were executed in multiple trades within stated price ranges, with full trade details available on request to regulators, the issuer, or security holders.

Who is the reporting person in IRMD’s Form 4 and what is their role?

The reporting person is Roger E. Susi, who serves as IRADIMED’s CEO, President, Chairman, director, and a more-than-10% owner. The reported transactions, however, occur through related trusts rather than direct personal accounts, reflecting his indirect ownership structure in the company’s common stock.

What is the Rule 10b5-1 trading plan mentioned in the IRMD filing?

The sales were made under a Rule 10b5-1 trading plan adopted on June 16, 2025. Such plans pre-schedule trades according to preset instructions, allowing insiders to sell shares over time under predetermined conditions, which can help separate trading activity from day-to-day informational decisions.

What IRADIMED shareholdings remain in the trusts after these transactions?

After the sales, the Phillip Susi 2008 Dynasty Trust held 2,262,500 shares, while the Roger E. Susi Revocable Trust held 162,950 shares. The filing also notes 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust, with Susi disclaiming beneficial ownership beyond his pecuniary interest.

Does Roger E. Susi claim full beneficial ownership of all reported IRMD shares?

No. He specifically disclaims beneficial ownership of shares held by the Matthew Susi 2008 Dynasty Trust, except for any pecuniary interest. This statement means those shares are reported for transparency but should not be assumed to be fully controlled or owned by him for Section 16 purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		S(1)		4,339	D	$100.54(2)	2,263,161	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	01/26/2026		S(1)		661	D	$101.38(3)	2,262,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(4)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $100.05 to $100.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $101.14 to $101.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.